Protagonist Therapeutics, Inc. (PTGX) financial statements (2021 and earlier)

Company profile

Business Address 7707 GATEWAY BLVD., SUITE 140
NEWARK, CA 94560-1160
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1338214478
Cash and cash equivalents338210621
Short-term investments100 3857
Restricted cash and investments0000
Receivables773 
Prepaid expense210 
Other current assets  11
Other undisclosed current assets34725
Total current assets:14513815183
Noncurrent Assets
Operating lease, right-of-use asset6
Property, plant and equipment2111
Long-term investments and receivables  1110
Long-term investments  1110
Restricted cash and investments000 
Deferred income tax assets1
Other noncurrent assets   0
Deferred tax assets, net1  
Total noncurrent assets:1021311
TOTAL ASSETS:15513916494
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1517116
Accounts payable3611
Accrued liabilities1211105
Deferred revenue18
Debt1   
Due to related parties11  
Contract with customer, liability8
Other undisclosed current liabilities  32 
Total current liabilities:3526436
Noncurrent Liabilities
Long-term debt and lease obligation6   
Operating lease, liability6
Liabilities, other than long-term debt2411 
Deferred revenue and credits1 
Deferred revenue24
Deferred rent credit 1
Other undisclosed noncurrent liabilities10   
Total noncurrent liabilities:4011 
Total liabilities:7527436
Stockholders' equity
Stockholders' equity attributable to parent8011312188
Additional paid in capital298253222152
Accumulated other comprehensive loss(0)(0)(0)(0)
Accumulated deficit(218)(140)(102)(65)
Total stockholders' equity:8011312188
TOTAL LIABILITIES AND EQUITY:15513916494

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenue, net20 
Sublease income0
Gross profit:03120 
Operating expenses(81)(73)(58)(33)
Other undisclosed operating income0   
Operating loss:(81)(42)(38)(33)
Nonoperating income3310
Investment income, nonoperating3310
Other nonoperating expense(0)  (0)
Interest and debt expense(0)   
Loss from continuing operations before income taxes:(78)(40)(37)(32)
Income tax expense (benefit)1(1)  
Loss before gain (loss) on sale of properties:(77)(41)(37)(32)
Other undisclosed net income 2  
Net loss:(77)(39)(37)(32)
Other undisclosed net loss attributable to parent   (5)
Net loss attributable to parent:(77)(39)(37)(37)
Preferred stock dividends and other adjustments   (1)
Net loss available to common stockholders, diluted:(77)(39)(37)(38)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(77)(39)(37)(32)
Other comprehensive loss   (0)
Comprehensive loss:(77)(39)(37)(33)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent0(0)0(5)
Comprehensive loss, net of tax, attributable to parent:(77)(39)(37)(37)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: